2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Buy
53
ARGX Quote, Financials, Valuation and Earnings
Last price:
$572.79
Seasonality move
:
16.13%
Day range:
$566.31 - $579.70
52-week range:
$361.26 - $678.21
Dividend yield:
0%
P/E ratio:
35.10x
P/S ratio:
14.31x
P/B ratio:
6.37x
Volume:
352.8K
Avg. volume:
416.4K
1-year change:
58.29%
Market cap:
$35B
Revenue:
$2.2B
EPS (TTM):
$16.33
Analysts' Opinion
-
Consensus Ratingargenx SE has received a consensus rating of Buy. The company's average rating is a Buy based on 14 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $753.80, argenx SE has an estimated upside of 31.49% from its current price of $573.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $560.72 representing 100% downside risk from its current price of $573.26.
Fair Value
-
According to the consensus of 15 analysts, argenx SE has 31.49% upside to fair value with a price target of $753.80 per share.
ARGX vs. S&P 500
-
Over the past 5 trading days, argenx SE has underperformed the S&P 500 by -3.23% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
argenx SE does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
argenx SE has grown year-over-year revenues for 11 quarters straight. In the most recent quarter argenx SE reported revenues of $790.7M.
Earnings Growth
-
argenx SE has grown year-over-year earnings for 0 quarters straight. In the most recent quarter argenx SE reported earnings per share of $2.58.
Enterprise value:
31.6B
EV / Invested capital:
--
Price / LTM sales:
14.31x
EV / EBIT:
86.65x
EV / Revenue:
12.26x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-24.78x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
86.65x
Gross Profit (TTM):
$2.3B
Return On Assets:
16.08%
Net Income Margin (TTM):
41.25%
Return On Equity:
21.33%
Return On Invested Capital:
18.03%
Operating Margin:
17.86%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $606.5M | $1.4B | $2.6B | $401M | $790.7M | |
| Gross Profit | $560.1M | $1.3B | $2.3B | $357.8M | $709.9M | |
| Operating Income | -$604.7M | -$408.8M | $215M | -$91.6M | $141.2M | |
| EBITDA | -$574M | -$301.4M | $365M | -$73.8M | $203.5M | |
| Diluted EPS | -$9.28 | -$5.67 | $16.33 | -$1.04 | $2.58 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | -- | |
| Total Assets | -- | -- | -- | -- | -- | |
| Current Liabilities | -- | -- | -- | -- | -- | |
| Total Liabilities | -- | -- | -- | -- | -- | |
| Total Equity | -- | -- | -- | -- | -- | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2023-06-30 | 2024-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$285.4M | -$124.7M | |
| Cash From Investing | -- | -- | -- | $527M | -$513.8M | |
| Cash From Financing | -- | -- | -- | $62.3M | $40.1M | |
| Free Cash Flow | -$656.9M | -$910.6M | -$1.3B | -$285.9M | -$147M | |
ARGX
Sector
Market Cap
$35B
$33.4M
Price % of 52-Week High
84.53%
45.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.66%
1-Year Price Total Return
58.29%
-40%
Beta (5-Year)
0.573
0.653
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$580.32
200-day SMA
Sell
Level
$589.42
Bollinger Bands (100)
Sell
Level
578.55 - 648.23
Chaikin Money Flow
Buy
Level
2.8M
20-day SMA
Sell
Level
$582.34
Relative Strength Index (RSI14)
Sell
Level
45.96
ADX Line
Sell
Level
20.4
Williams %R
Neutral
Level
-33.9683
50-day SMA
Sell
Level
$589.38
MACD (12, 26)
Sell
Level
-5.49
25-day Aroon Oscillator
Sell
Level
-12
On Balance Volume
Neutral
Level
14.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (32.697)
Buy
CA Score
(Annual)
Level (1.5727)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-4.7107)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart’s intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Stock Forecast FAQ
In the current month, ARGX has received 14 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ARGX average analyst price target in the past 3 months is $753.80.
-
Where Will argenx SE Stock Be In 1 Year?
According to analysts, the consensus estimate is that argenx SE share price will rise to $753.80 per share over the next 12 months.
-
What Do Analysts Say About argenx SE?
Analysts are divided on their view about argenx SE share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that argenx SE is a Sell and believe this share price will drop from its current level to $560.72.
-
What Is argenx SE's Price Target?
The price target for argenx SE over the next 1-year time period is forecast to be $753.80 according to 15 Wall Street analysts, 14 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ARGX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for argenx SE is a Buy. 14 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ARGX?
You can purchase shares of argenx SE via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase argenx SE shares.
-
What Is The argenx SE Share Price Today?
argenx SE was last trading at $572.79 per share. This represents the most recent stock quote for argenx SE. Yesterday, argenx SE closed at $573.26 per share.
-
How To Buy argenx SE Stock Online?
In order to purchase argenx SE stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Asana Stock Be in 5 Years?
Asana stock hasn’t given many investors on Wall Street any…
Where Will Dell Stock Be in 5 Years?
So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
